Compare GILT & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | BCRX |
|---|---|---|
| Founded | 1987 | 1986 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.6B |
| IPO Year | 1997 | 1995 |
| Metric | GILT | BCRX |
|---|---|---|
| Price | $16.07 | $8.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $20.00 | ★ $20.82 |
| AVG Volume (30 Days) | 1.1M | ★ 4.0M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $11.72 | $12.55 |
| P/E Ratio | $42.82 | ★ $7.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.30 | $6.00 |
| 52 Week High | $20.38 | $11.31 |
| Indicator | GILT | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 69.72 |
| Support Level | $13.11 | $7.95 |
| Resistance Level | $20.38 | $8.68 |
| Average True Range (ATR) | 0.83 | 0.33 |
| MACD | 0.15 | 0.12 |
| Stochastic Oscillator | 59.91 | 81.19 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.